Literature DB >> 30597643

Factors at de novo donor-specific antibody initial detection associated with allograft loss: a multicenter study.

Carrie A Schinstock1, Darshana M Dadhania2, Matthew J Everly3, Byron Smith4, Manish Gandhi5, Evan Farkash6, Vijay K Sharma2, Milagros Samaniego-Picota7, Mark D Stegall1.   

Abstract

We aimed to evaluate patient factors including nonadherence and viral infection and de novo donor-specific antibody (dnDSA) characteristics [total immunoglobulin G (IgG), C1q, IgG3, and IgG4] as predictors of renal allograft failure in a multicenter cohort with dnDSA. We performed a retrospective observational study of 113 kidney transplant recipients with dnDSA and stored sera for analysis. Predictors of death-censored allograft loss were assessed by Cox proportional modeling. Death-censored allograft survival was 77.0% (87/113) during a median follow-up of 2.2 (IQR 1.2-3.7) years after dnDSA detection. Predictors of allograft failure included medication nonadherence [HR 6.5 (95% CI 2.6-15.9)], prior viral infection requiring immunosuppression reduction [HR 5.3 (95% CI 2.1-13.5)], IgG3 positivity [HR 3.8 (95% CI 1.5, 9.3)], and time post-transplant (years) until donor-specific antibody (DSA) detection [HR 1.2 (95% CI 1.0, 1.3)]. In the 67 patients who were biopsied at dnDSA detection, chronic antibody-mediated rejection [HR 11.4 (95% CI 2.3, 56.0)] and mixed rejection [HR 7.4 (95% CI 2.2, 24.8)] were associated with allograft failure. We conclude that patient factors, including a history of viral infection requiring immunosuppression reduction or medication nonadherence, combined with DSA and histologic parameters must be considered to understand the risk of allograft failure in patients with dnDSA.
© 2019 Steunstichting ESOT.

Entities:  

Keywords:  HLA-antibody post-transplantation; histocompatibility and immunogenetics; infection; kidney clinical; other; rejection

Mesh:

Substances:

Year:  2019        PMID: 30597643      PMCID: PMC6483899          DOI: 10.1111/tri.13395

Source DB:  PubMed          Journal:  Transpl Int        ISSN: 0934-0874            Impact factor:   3.782


  35 in total

1.  Banff '05 Meeting Report: differential diagnosis of chronic allograft injury and elimination of chronic allograft nephropathy ('CAN').

Authors:  K Solez; R B Colvin; L C Racusen; B Sis; P F Halloran; P E Birk; P M Campbell; M Cascalho; A B Collins; A J Demetris; C B Drachenberg; I W Gibson; P C Grimm; M Haas; E Lerut; H Liapis; R B Mannon; P B Marcus; M Mengel; M J Mihatsch; B J Nankivell; V Nickeleit; J C Papadimitriou; J L Platt; P Randhawa; I Roberts; L Salinas-Madriga; D R Salomon; D Seron; M Sheaff; J J Weening
Journal:  Am J Transplant       Date:  2007-03       Impact factor: 8.086

2.  Banff 07 classification of renal allograft pathology: updates and future directions.

Authors:  K Solez; R B Colvin; L C Racusen; M Haas; B Sis; M Mengel; P F Halloran; W Baldwin; G Banfi; A B Collins; F Cosio; D S R David; C Drachenberg; G Einecke; A B Fogo; I W Gibson; D Glotz; S S Iskandar; E Kraus; E Lerut; R B Mannon; M Mihatsch; B J Nankivell; V Nickeleit; J C Papadimitriou; P Randhawa; H Regele; K Renaudin; I Roberts; D Seron; R N Smith; M Valente
Journal:  Am J Transplant       Date:  2008-02-19       Impact factor: 8.086

3.  Evolution and clinical pathologic correlations of de novo donor-specific HLA antibody post kidney transplant.

Authors:  C Wiebe; I W Gibson; T D Blydt-Hansen; M Karpinski; J Ho; L J Storsley; A Goldberg; P E Birk; D N Rush; P W Nickerson
Journal:  Am J Transplant       Date:  2012-03-19       Impact factor: 8.086

4.  Terminal complement inhibition decreases antibody-mediated rejection in sensitized renal transplant recipients.

Authors:  M D Stegall; T Diwan; S Raghavaiah; L D Cornell; J Burns; P G Dean; F G Cosio; M J Gandhi; W Kremers; J M Gloor
Journal:  Am J Transplant       Date:  2011-09-22       Impact factor: 8.086

5.  Frequency and clinical implications of development of donor-specific and non-donor-specific HLA antibodies after kidney transplantation.

Authors:  Maryvonne Hourmant; Anne Cesbron-Gautier; Paul I Terasaki; Kazuo Mizutani; Anne Moreau; Aurélie Meurette; Jacques Dantal; Magali Giral; Gilles Blancho; Diego Cantarovich; Georges Karam; Gilles Follea; Jean-Paul Soulillou; Jean-Denis Bignon
Journal:  J Am Soc Nephrol       Date:  2005-07-13       Impact factor: 10.121

6.  Persistent strong anti-HLA antibody at high titer is complement binding and associated with increased risk of antibody-mediated rejection in heart transplant recipients.

Authors:  Adriana Zeevi; John Lunz; Brian Feingold; Michael Shullo; Christian Bermudez; Jeffery Teuteberg; Steven Webber
Journal:  J Heart Lung Transplant       Date:  2012-11-09       Impact factor: 10.247

7.  Novel C1q assay reveals a clinically relevant subset of human leukocyte antigen antibodies independent of immunoglobulin G strength on single antigen beads.

Authors:  G Chen; F Sequeira; D B Tyan
Journal:  Hum Immunol       Date:  2011-07-18       Impact factor: 2.850

8.  Chronic humoral rejection: identification of antibody-mediated chronic renal allograft rejection by C4d deposits in peritubular capillaries.

Authors:  Shamila Mauiyyedi; Patricia Della Pelle; Susan Saidman; A Bernard Collins; Manuel Pascual; Nina E Tolkoff-Rubin; Winfred W Williams; A Benedict Cosimi; Eveline E Schneeberger; Robert B Colvin
Journal:  J Am Soc Nephrol       Date:  2001-03       Impact factor: 10.121

9.  Clinical usefulness of a novel C1q assay to detect immunoglobulin G antibodies capable of fixing complement in sensitized pediatric heart transplant patients.

Authors:  Clifford Chin; Ge Chen; Flavia Sequeria; Gerald Berry; Stephanie Siehr; Daniel Bernstein; David Rosenthal; Olaf Reinhartz; Dolly Tyan
Journal:  J Heart Lung Transplant       Date:  2010-10-15       Impact factor: 10.247

10.  Clinical significance of post kidney transplant de novo DSA in otherwise stable grafts.

Authors:  James E Cooper; Jane Gralla; Laurence Chan; Alexander C Wiseman
Journal:  Clin Transpl       Date:  2011
View more
  2 in total

1.  Belatacept Treatment of Recurrent Late-onset T Cell-mediated Rejection/Antibody-mediated Rejection With De Novo Donor-specific Antibodies in a Liver Transplant Patient.

Authors:  Göran B Klintmalm; James F Trotter; Anthony Demetris
Journal:  Transplant Direct       Date:  2022-06-24

Review 2.  Recommended Treatment for Antibody-mediated Rejection After Kidney Transplantation: The 2019 Expert Consensus From the Transplantion Society Working Group.

Authors:  Carrie A Schinstock; Roslyn B Mannon; Klemens Budde; Anita S Chong; Mark Haas; Stuart Knechtle; Carmen Lefaucheur; Robert A Montgomery; Peter Nickerson; Stefan G Tullius; Curie Ahn; Medhat Askar; Marta Crespo; Steven J Chadban; Sandy Feng; Stanley C Jordan; Kwan Man; Michael Mengel; Randall E Morris; Inish O'Doherty; Binnaz H Ozdemir; Daniel Seron; Anat R Tambur; Kazunari Tanabe; Jean-Luc Taupin; Philip J O'Connell
Journal:  Transplantation       Date:  2020-05       Impact factor: 5.385

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.